Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report

Rearranged during transfection (RET)‑activated gliomas are exceptionally rare and associated with a poor prognosis, and there are no established effective therapies. Clinical data on RET inhibitors are predominantly derived from solid tumors such as non‑small cell lung cancer and medullary thyroid carcinoma, with data for central nervous system tumors being scarce. The present report describes a case of pleomorphic xanthoastrocytoma with RET activation that progressed following the Stupp regimen but subsequently exhibited a favorable response to pralsetinib, teniposide and bevacizumab. The tumor area decreased from 4.84 cm2 before treatment to 1.92 cm2 (calculated based on the longest and maximum perpendicular diameters).

Authors

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2026-11-19
DOI
https://doi.org/10.3892/etm.2026.13364
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report

ShiZhen Zhou, Rongjie Tao, XueQiang Pan, Yueliang Zheng et al.
Experimental and Therapeutic Medicine
Glioma Diagnosis and Treatment
article

Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report

ShiZhen Zhou, Rongjie Tao, XueQiang Pan, Yueliang Zheng, Peng Sun, Yan Li, Huayang Zhao, Hui Wang
article en

Abstract

Rearranged during transfection (RET)‑activated gliomas are exceptionally rare and associated with a poor prognosis, and there are no established effective therapies. Clinical data on RET inhibitors are predominantly derived from solid tumors such as non‑small cell lung cancer and medullary thyroid carcinoma, with data for central nervous system tumors being scarce. The present report describes a case of pleomorphic xanthoastrocytoma with RET activation that progressed following the Stupp regimen but subsequently exhibited a favorable response to pralsetinib, teniposide and bevacizumab. The tumor area decreased from 4.84 cm2 before treatment to 1.92 cm2 (calculated based on the longest and maximum perpendicular diameters).

Experimental and Therapeutic MedicineVol. 33(1)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon